作者
Rajasree Menon, Edgar A Otto, Rachel Sealfon, Viji Nair, Aaron K Wong, Chandra L Theesfeld, Xi Chen, Yuan Wang, Avinash S Boppana, Jinghui Luo, Yingbao Yang, Peter M Kasson, Jennifer A Schaub, Celine C Berthier, Sean Eddy, Chrysta C Lienczewski, Bradley Godfrey, Susan L Dagenais, Ryann Sohaney, John Hartman, Damian Fermin, Lalita Subramanian, Helen C Looker, Jennifer L Harder, Laura H Mariani, Jeffrey B Hodgin, Jonathan Z Sexton, Christiane E Wobus, Abhijit S Naik, Robert G Nelson, Olga G Troyanskaya, Matthias Kretzler
发表日期
2020/12/1
期刊
Kidney international
卷号
98
期号
6
页码范围
1502-1518
出版商
Elsevier
简介
COVID-19 morbidity and mortality are increased in patients with diabetes and kidney disease via unknown mechanisms. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) for entry into host cells. Since ACE2 is a susceptibility factor for infection, we investigated how diabetic kidney disease and medications alter ACE2 receptor expression in kidneys. Single cell
RNA profiling of healthy living donor and kidney biopsies from patients with diabetic kidney disease revealed ACE2 expression primarily in proximal tubular epithelial cells. This cell specific localization was confirmed by in situ hybridization. ACE2 expression levels were unaltered by exposures to renin angiotensin aldosterone system inhibitors in diabetic kidney disease. Bayesian integrative analysis of a large compendium of public-omics datasets identified molecular network modules induced in ACE2-expressing proximal tubular epithelial cells in …
引用总数
2020202120222023202422633163